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Accepted 15 March 2012AbstractObjective: To identify associations between the interleukin-1b gene and preeclampsia in Taiwanese women.
Methods and Materials: We genotyped Taiwanese population (102 women with preeclampsia and 148 controls) for two polymorphisms of the
interleukin-1b gene (promoter region and Exon 5) by using polymerase chain reaction and restriction fragment length polymorphism analysis.
The association between the genotype and disease was examined by Chi-square tests.
Results: We found no association between the two polymorphic sites of interleukin-1b gene and preeclampsia. No significant differences were
detected in genotype distributions and allele frequencies of the AvaI polymorphism at position 511 in the promoter region and the TaqI
polymorphism at position þ3953 within Exon 5.
Conclusion: Our data do not support a role of the interleukin-1b gene in the pathogenesis of preeclampsia in Taiwanese women.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Preeclampsia is one of the major and crucial problems in
obstetrics [1]. It is characterized by the new onset of hyper-
tension and proteinuria after the 20th week of gestation and
occurs in about 6% to 10% of all pregnancies and results in
substantial maternal and fetal morbidity and mortality [1]. The
underlying etiology of preeclampsia remains unknown even in
the 21st century despite extensive research into its pathogen-
esis. Several pathophysiologic abnormalities such as abnormal* Corresponding authors. Department of Obstetrics and Gynecology,
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doi:10.1016/j.tjog.2012.04.014trophoblast differentiation and invasion, placental and endo-
thelial dysfunction, immune maladaptation, and exaggerated
systemic inflammatory response have been proposed to
explain the development of preeclampsia [2,3]. Among them,
a genetic component in preeclampsia cannot be neglected.
Since 1968, preeclampsia has been proposed to be a genetic
disease [4e8]. Chesley and Cooper [5] claimed that a possible
single gene may be responsible for preeclampsia. To date,
a variety of genes have been tested to be associated with
preeclampsia and the results remained controversial. In 1999,
Dr Broughton Pipkin advocated that it is unlikely that there is
only a single gene and that a cluster of polymorphisms of
genes, possibly in conjunction with environmental factors,
predispose to the development of preeclampsia [9]. In other
words, several candidate genes must be investigated to identify
the disease-gene association in preeclampsia.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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known completely, a central pathophysiologic feature is
systemic inflammation, which secondarily involves wide-
spread endothelial dysfunction [10,11]. Redman et al [11]
considered preeclampsia to be an excessive maternal inflam-
matory response to pregnancy. Levels of plasma and placental
proinflammatory cytokines are higher in pregnant women with
preeclampsia, which implies that cytokines might play an
important role in the pathogenesis of preeclampsia [12e20].
An exaggerated inflammatory response to pregnancy may
occur in genetically susceptible women, such as those who
carry cytokine gene polymorphisms that are known to up-
regulate cytokine production [10e20].
Interleukin-1b (IL-1b) is a proinflammatory cytokine
produced by monocytes, macrophages, and epithelial cells and
secretion of IL-1b leads to a proinflammatory cascade,
including production of tumor necrosis factor a, interferon g,
interleukin-2, and interleukin-12 [10e20]. Many studies have
investigated the influence of IL-1b on preeclampsia [10e22]. In
preeclampsia, increased placental expression of IL-1b has been
observed and is considered to elevate circulating cytokines
levels [12e20]. However, in the previous studies examining the
relationship between the IL-1b genotypes and preeclampsia,
only small sample sizes were used [21], and no significant
differenceswere found [21,22]. To the best of our knowledge, no
study had investigated the relationship between IL-1b geno-
types and preeclampsia in Taiwanese women. Since the preva-
lence of polymorphisms varies in different populations, we
tested the hypothesis that the polymorphisms within the IL-1b
gene are an important risk factor for preeclampsia in Taiwanese
women.
Materials and methodsSubjectsThis study was approved by the National Cheng Kung
University Hospital (NCKUH) Institutional Review Board
(IRB No: HR-95-43 and HR-100-066), and all participants
gave written informed consent.
From August 2006 to July 2011 at the Department of
Obstetrics and Gynecology of NCKUH, we retrospectively
collected 102 cases of severe preeclampsia, HELLP syndrome
(hemolysis, elevated liver enzymes, and low platelet count), or
eclampsia meeting the criteria of the American College of
Obstetricians and Gynecologists [23,24], and another 148
normal controls. They all delivered at the Department of
Obstetrics and Gynecology of NCKUH, between January 2006
and December 2010. Patients with severe preeclampsia,
HELLP syndrome, or eclampsia were collected from the
medical records of NCKUH. They were called back and asked
to sign an informed consent at that time. During the same time,
blood samples were collected from the normal controls who
had given birth in NCKUH after uncomplicated pregnancies.
All study participants were matched for maternal age within 5
years, gestational age, parity, and fetal sex. None of the normal
controls had clinical signs of preeclampsia or other medical orpregnancy complications. None of the study participants were
in labor at the time of blood sampling. Both groups were
ethnically Taiwanese and were enrolled by random selection
in this study.
Preeclampsia was defined as the development of hyperten-
sion that occurred in a pregnant woman known to be normo-
tensive previously after 20 weeks of gestation, accompanied by
new-onset proteinuria [3,23,24]. Hypertension was defined as
a systolic blood pressure 140 mmHg or a diastolic blood
pressure 90 mmHg on at least two occasions and 4 to 6 hours
apart after the 20th week of gestation in women known to be
normotensive previously [23,24]. Proteinuria was defined as
300mg or more protein excretion in 24-hour urine collection, or
protein concentration of 300 mg/L or higher in urine (1þ on
dipstick) [3,23,24]. Severe preeclampsiawas diagnosed if one or
more of the following were present: blood pressure of 160/
110mmHg or higher, excretion of 5 g or more of protein in a 24-
hour urine sample, the presence ofmultiorgan involvement such
as oliguria, pulmonary edema, visual or cerebral disturbance,
pain in the epigastric area or right upper quadrant, abnormal
liver enzymes, and thrombocytopenia (platelet count
<100  109/L) [3,23,24]. To diagnose HELLP syndrome, the
following criteria had to bemet: hemolysis, defined by increased
lactic dehydrogenase (600 IU/L); elevated liver enzyme levels
(aspartate aminotransferase and alanine aminotransferase
70 IU/L); and thrombocytopenia [3,23,24]. Eclampsia was
defined as the onset of convulsion in awomanwith preeclampsia
[3,23,24]. Gestational age was based on the precise date of the
last menstrual period and/or ultrasound measurement of the
crown-rump length in the first trimester. Women who met
preeclampsia criteria but not severe preeclampsiawere excluded
from the study. Other exclusion criteria were as follows:
multiple pregnancies, premature rupture of membranes, cho-
rioamnionitis, chronic hypertension, diabetes mellitus, auto-
immune disorders or fetal abnormalities.Genetic studiesThe methods described by Hefler et al [21] were used to
examine polymorphisms of the IL-1b gene (promoter region
and Exon 5). The IL-1bgene is located on the long arm of
Chromosome 2 at position 2q12-14 [22]. Two di-allelic
polymorphisms located in the IL-1b gene were checked: the
AvaI polymorphism at position 511 in the promoter region
and the TaqI polymorphism at position þ3953 within Exon 5
[22]. Blood samples were obtained from a peripheral vein and
then DNA was extracted from blood using the Puregene DNA
Purification Kit (Gentra Systems, Inc. Minneapolis, MN,
USA) and stored at 4 C until analyzed [21]. The AvaI poly-
morphism at position 511 in the promoter region of IL-1b
gene was searched by using a polymerase chain reaction
(PCR) strategy as published by di Giovine et al [25]. For
testing the TaqI polymorphism at position þ3953 within Exon
5 of the IL-1b gene, PCR amplification was followed
by restriction fragment length polymorphism analysis as
previously described [26,27]. The target DNA sequence at
position 511 in the IL1-b gene promoter was amplified using
Table 2
Allele frequencies of the AvaI polymorphism at position 511 in the promoter
region of IL-1b gene among women with severe preeclampsia and normal
controls.
Numbers of
alleles (2n)
Allele frequencies c2 p-value
2n C T
Normal controls 296 152
(51.4%)
144
(48.6%)
2.53 0.11
Women with severe
preeclampsiaa
204 90
(44.1%)
114
(55.9%)
a Women with HELLP syndrome or eclampsia were also included.
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primer 50-GTT TAG GAA TCT TCC CAC TT-30 [21]. The
target DNA sequence in the IL1-b gene Exon 5 was amplified
using primer 50-GTT GTC ATC AGA CTT TGA CC-30 and
reverse primer 50-TTC AGT TCATAT GGA CCA GA-30 [21].
For new mutations or variations in the PCR products of the IL-
1b gene promoter and the IL-1b gene Exon 5, single strand
conformation polymorphism (SSCP) and denaturing gradient
gel electrophoresis (DGGE) were used [28]. We also did direct
sequencing for the representative samples or equivocal results
detected by SSCP and DGGE as described by Chang and
Kidd [29].Statistical analysisGenotype and allele frequencies were compared by c2
testing, using the statistical package SPSS (SPSS Inc,
Chicago, Illinois, USA). Yates correction of continuity was
used when an observed number was 5. A p-value < 0.05 was
considered statistically significant.
Results
Genotype distributions and allele frequencies of the AvaI
polymorphism at position 511 in the promoter region of the
IL-1b gene among women with severe preeclampsia and
normal controls are given in Tables 1 and 2. Genotype was
determined in the 102 women with severe preeclampsia
(including HELLP syndrome and eclampsia) and 148 normal
controls. Overall, three genotypes (C/C, C/T, T/T) and two
alleles (C, T) were seen. The frequency of homozygotes (T/T)
was 35.3% (36 of 102) in women with severe preeclampsia
group and 25.0% (37 of 148) in normal controls. The
frequency of T alleles was 55.9% (114 of 204 alleles) in
women with severe preeclampsia group and 48.6% (144 of
296 alleles) in normal controls. For the AvaI polymorphism at
position 511, neither genotype distributions nor allele
frequencies showed statistically significant differences among
the women with severe preeclampsia and normal controls.
Genotype distributions and allele frequencies of the TaqI
polymorphism at position þ3953 within Exon 5 of the IL-1b
gene among women with severe preeclampsia and normal
controls are given in Tables 3 and 4. Genotyping data for this
polymorphism were only available in the 95 women withTable 1
Genotype distributions of the AvaI polymorphism at position 511 in the
promoter region of IL-1b gene among women with severe preeclampsia and
normal controls.
Numbers
of cases (n)
Genotype distributions c2 p-value
n CC CT TT
Normal controls 148 41
(27.7%)
70
(47.3%)
37
(25.0%)
3.1 0.21
Women with severe
preeclampsiaa
102 24
(23.5%)
42
(41.2%)
36
(35.3%)
a Women with HELLP syndrome or eclampsia were also included.severe preeclampsia (including HELLP syndrome and
eclampsia) and 144 normal controls. For 11 women, the PCR
was unsuccessful after repeated attempts when testing the
TaqI polymorphism at position þ3953. Overall, two genotypes
(C/C, C/T) and two alleles (C, T) were seen. The homozygotes
(T/T) could not be detected in both severe preeclampsia and
control groups among Taiwanese women. The allele frequency
of T alleles was 2.1% (4 of 190 alleles) in the women with
severe preeclampsia and 1.7% (5 of 288 alleles) in normal
controls. No statistically significant differences were observed
in genotype distributions and allele frequencies of the TaqI
polymorphism at position þ3953 among women with severe
preeclampsia and normal controls.Discussion
Since preeclampsia implies a genetic susceptibility [4e9],
it is of interest to investigate which specific genetic loci are
involved. Determination of such genetic factors would assist in
identifying women at risk. In the present study, we did not find
an association between the polymorphisms of IL-1b gene and
preeclampsia, especially severe preeclampsia. Our study is the
first investigating for the association between the poly-
morphisms of IL-1b gene and preeclampsia in Taiwanese
women. Because the ethnic difference might play an important
role in disease-gene association studies [30], we cannot adopt
the conclusion from other countries without our own studies in
the Taiwanese population. From our results, we can rule out
the role of IL-1b gene polymorphisms in the pathogenesis of
preeclampsia in Taiwanese women. Our conclusions were
similar to previous studies in Hispanic and Dutch populations
described by Helfer et al and Lachmeijer et al, whichTable 3
Genotype distributions of the TaqI polymorphism at position þ3953 within
exon 5 of IL-1b gene among women with severe preeclampsia and normal
controls.
Number of
cases (n)
Genotype distributions c2 p-value
n CC CT TT
Normal controls 144 139
(96.5%)
5
(3.5%)
0
(0.0%)
0.53 0.77
Women with severe
preeclampsiaa
95 91
(95.8%)
4
(4.2%)
0
(0.0%)
a Women with HELLP syndrome or eclampsia were also included.
Table 4
Allele frequencies of the TaqI polymorphism at position þ3953 within exon 5
of IL-1b gene among women with severe preeclampsia and normal controls.
Number of
alleles (2n)
Allele number
(frequency)
c2 p-value
2n C T
Normal controls 288 283
(98.3%)
5
(1.7%)
0.09 0.77
Women with severe
preeclampsiaa
190 186
(97.9%)
4
(2.1%)
a Women with HELLP syndrome or eclampsia were also included.
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and Exon 5 of the IL-1b gene were not associated with the risk
for preeclampsia [21,22].
There are several possible hypotheses that could explain
our results. One explanation is the definition of pregnancy
complications. For example, the severity of preeclampsia
might affect the results [31]. The diagnostic criteria for
preeclampsia used in our study were the same as previous
studies investigating for the role of IL-1b gene polymorphisms
in the pathogenesis of preeclampsia [21,22]. In our present
study, women who met preeclampsia criteria but not severe
preeclampsia were excluded from the study. In other studies,
women with mild preeclampsia were included by Helfer et al
[21], while Lachmeijer et al recruited women with
preeclampsia, severe preeclampsia, HELLP syndrome, and
eclampsia in the study group [22]. However, all the results
showed that polymorphisms of the IL-1b gene promoter and
Exon 5 were not associated with the risk for preeclampsia.
Another explanation for the negative results is the difference
in prevalence of IL-1b gene polymorphisms and preclampsia in
different populations. When the prevalence of IL1-b gene
polymorphisms is very low in the population, the relatively
small sample size increases the likelihood of a type II error [31].
In our results, especially the genotype distributions and allele
frequencies of the TaqI polymorphism at positionþ3953 within
Exon 5 of the IL1-b gene among women with severe
preeclampsia and normal controls, the homozygotes (T/T)
could not be observed in both severe preeclampsia and control
groups and the allele frequency of T alleles was only 2.1% in
women with severe preeclampsia group and 1.7% in normal
controls, even though genotyping data for this polymorphism
were available in the 95 women with severe preeclampsia and
144 normal controls. The prevalence of IL-1b gene poly-
morphisms is much lower in Taiwanesewomen when compared
with Hispanic and Dutch populations [21,22]. It would be much
more challenging to recruit more study patients to test the
relationship between the polymorphisms within the IL-1b gene
and the risk for preeclampsia in the Taiwanese women.
Another reason for our negative results could be the
complex interactions among genetic and environmental
factors [32]. While preeclampsia is generally considered to be
a multifactorial disease, environmental risk factors for
preeclampsia pathophysiology, such as diet, obesity, stress,
smoking, and other social elements during pregnancy may
influence the development of preeclampsia and theseenvironmental factors may be very different among races [33].
A limitation of our study is that we did not analyze the
interaction and co-morbidity among environmental risk
factors, polymorphisms of IL-1b gene and preeclampsia.
In conclusion, preeclampsia has an inherited component
likely to involve many genes [31]. In this series, we observed
that polymorphisms of the IL-1b gene do not play a major role
in the development of preeclampsia in the Taiwanese women.
Multilocus or haplotype analysis, rather than a single locus
study, might be a preferable strategy in future investigations to
obtain much more accurate results between genetic suscepti-
bility and preeclampsia.Acknowledgments
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